Table 2

Summary of baseline characteristics and primary composite cardiovascular outcomes of the completed CVOTs for GLP-1 RA

GLP-1 RA: Study nameNo. of patientsMedian follow-up (years)% with CV disease*% of statin useBaseline ageBaseline HgA1cBaseline BMIPrimary composite CV outcome HR (95% CI)P value
Lixisenatide: ELIXA60682.1100%93%60.37.7%30.11.02 (0.89 to 1.17)0.81
Liraglutide: LEADER93403.881%72%64.38.7%32.50.87 (0.78 to 0.97)0.01
Semaglutide: SUSTAIN-632972.160%73%64.68.7%32.80.74 (0.58 to 0.95)0.02
Exenatide QW: EXSCEL147523.273.1%74%62.08.0%31.80.91 (0.83 to 1.00)0.06
Albiglutide: Harmony94631.6100%84%64.18.7%32.30.78 (0.68 to 0.90)0.0006
Dulaglutide: REWIND99015.431.5%66%66.27.2%32.30.88 (0.79 to 0.99)0.026
Oral semaglutide: PIONEER 631831.384.7%85%66.08.2%32.30.79 (0.57 to 1.11)0.17
  • *Remaining participants with cardiovascular risk factors.

  • BMI, body mass index;CV, cardiovascular; HgA1c, glycated haemoglobin.